Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5205906
Max Phase: Preclinical
Molecular Formula: C56H83N15O12S2Se
Molecular Weight: 1301.47
Associated Items:
ID: ALA5205906
Max Phase: Preclinical
Molecular Formula: C56H83N15O12S2Se
Molecular Weight: 1301.47
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)CCCCCn2[se]c3ccccc3c2=O)C(=O)N[C@@H](CCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1)C(=O)O
Standard InChI: InChI=1S/C56H83N15O12S2Se/c1-31(2)26-41(55(82)83)68-52(79)43-30-85-84-29-42(63-45(73)20-5-4-12-25-71-54(81)35-15-7-9-19-44(35)86-71)51(78)65-39(21-23-58)49(76)64-38(18-13-24-61-56(59)60)47(74)67-40(27-33-28-62-36-16-8-6-14-34(33)36)50(77)70-46(32(3)72)53(80)66-37(48(75)69-43)17-10-11-22-57/h6-9,14-16,19,28,31-32,37-43,46,62,72H,4-5,10-13,17-18,20-27,29-30,57-58H2,1-3H3,(H,63,73)(H,64,76)(H,65,78)(H,66,80)(H,67,74)(H,68,79)(H,69,75)(H,70,77)(H,82,83)(H4,59,60,61)/t32-,37+,38+,39+,40+,41+,42+,43+,46+/m1/s1
Standard InChI Key: XOMPJILWCZDAOR-IQPXMTETSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1301.47 | Molecular Weight (Monoisotopic): 1301.4952 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Liu J, Xu S, Huang C, Shen J, Yu S, Yu Y, Sun Q, Dai Q.. (2022) Synthesis and activity evaluation of selenazole-coupled CPI-1 irreversible bifunctional inhibitors for botulinum toxin A light chain., 73 [PMID:35914651] [10.1016/j.bmcl.2022.128913] |
Source(1):